|BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.|
|PMID: 17173546 Owner: NLM Status: MEDLINE|
|We have previously shown that heat shock protein (Hsp) 27 or its upstream activator p38 mitogen-activated protein kinase (MAPK) confers resistance to bortezomib and dexamethasone (Dex) in multiple myeloma (MM) cells. This study examined anti-MM activity of a novel p38 MAPK inhibitor, BIRB 796, alone and in combination with conventional and novel therapeutic agents. BIRB 796 blocked baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. The Hsp90 inhibitor 17-allylamino-17-demethoxy-geldanamycin (17-AAG) upregulated protein expression and phosphorylation of Hsp27; conversely, BIRB 796 inhibited this phosphorylation and enhanced 17-AAG-induced cytotoxicity. Importantly, BIRB 796 inhibited Hsp27 phosphorylation induced by 17-AAG plus bortezomib, thereby enhancing cytotoxicity. In bone marrow stromal cells (BMSC), BIRB 796 inhibited phosphorylation of p38 MAPK and secretion of interleukin-6 (IL-6) and vascular endothelial growth factor triggered by either tumour necrosis factor-alpha or tumour growth factor-beta1. BIRB 796 also inhibited IL-6 secretion induced in BMSCs by adherence to MM cells, thereby inhibiting tumour cell proliferation. These studies therefore suggest that BIRB 796 overcomes drug-resistance in the BM microenvironment, providing the framework for clinical trials of a p38 MAPK inhibitor, alone and in combination with bortezomib, Hsp90 inhibitor, or Dex, to improve patient outcome in MM.|
|Hiroshi Yasui; Teru Hideshima; Hiroshi Ikeda; Janice Jin; Enrique M Ocio; Tanyel Kiziltepe; Yutaka Okawa; Sonia Vallet; Klaus Podar; Kenji Ishitsuka; Paul G Richardson; Chris Pargellis; Neil Moss; Noopur Raje; Kenneth C Anderson|
Related Documents :
|12517926 - Cutting edge: proliferating fibroblasts respond to collagenous c1q with phosphorylation...
16307586 - Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhi...
21868386 - Involvement of 14-3-3 proteins in the second epidermal growth factor-induced wave of ra...
19619936 - The dopamine-somatostatin chimeric compound bim-23a760 exerts antiproliferative and cyt...
1663396 - The participation of camp and protein kinase c in the regulation of aldosterone biosynt...
9268696 - Bradykinin induces actin reorganization and enhances cell motility in hacat keratinocytes.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2006-12-14|
|Title: British journal of haematology Volume: 136 ISSN: 0007-1048 ISO Abbreviation: Br. J. Haematol. Publication Date: 2007 Feb|
|Created Date: 2007-01-19 Completed Date: 2007-03-29 Revised Date: 2009-11-19|
Medline Journal Info:
|Nlm Unique ID: 0372544 Medline TA: Br J Haematol Country: England|
|Languages: eng Pagination: 414-23 Citation Subset: IM|
|Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Agents, Hormonal
Apoptosis / drug effects
Benzoquinones / therapeutic use
Boronic Acids / therapeutic use
Cell Adhesion / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Cytotoxicity Tests, Immunologic
Dexamethasone / therapeutic use
Drug Resistance, Neoplasm / drug effects*
HSP90 Heat-Shock Proteins / antagonists & inhibitors, metabolism
Immunoblotting / methods
Interleukin-6 / secretion
Intracellular Signaling Peptides and Proteins
Lactams, Macrocyclic / therapeutic use
Multiple Myeloma / drug therapy*, metabolism, pathology
Naphthalenes / pharmacology, therapeutic use*
Protein Kinase Inhibitors / pharmacology, therapeutic use*
Protein-Serine-Threonine Kinases / antagonists & inhibitors*, metabolism
Pyrazines / therapeutic use
Pyrazoles / pharmacology, therapeutic use*
Signal Transduction / drug effects*
Transforming Growth Factor beta / pharmacology
Tumor Necrosis Factor-alpha / pharmacology
Vascular Endothelial Growth Factor A / secretion
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors, metabolism
|IP50 CA10070/CA/NCI NIH HHS; P0-1 78378//PHS HHS; R0-1 CA50947/CA/NCI NIH HHS|
|0/17-(allylamino)-17-demethoxygeldanamycin; 0/Antineoplastic Agents, Hormonal; 0/BIRB 796; 0/Benzoquinones; 0/Boronic Acids; 0/HSP90 Heat-Shock Proteins; 0/Interleukin-6; 0/Intracellular Signaling Peptides and Proteins; 0/Lactams, Macrocyclic; 0/Naphthalenes; 0/Protein Kinase Inhibitors; 0/Pyrazines; 0/Pyrazoles; 0/Transforming Growth Factor beta; 0/Tumor Necrosis Factor-alpha; 0/Vascular Endothelial Growth Factor A; 0/bortezomib; 50-02-2/Dexamethasone; EC 2.7.1.-/MAP-kinase-activated kinase 2; EC 220.127.116.11/Protein-Serine-Threonine Kinases; EC 18.104.22.168/p38 Mitogen-Activated Protein Kinases|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Telomerase activity coevolves with body mass not lifespan.
Next Document: HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.